ArticleOrganic letters2025
Giant Fully Fused Tetrapodal Rylenimides: Design, Synthesis and Optoelectrochemical Characterization via Alkyl Chain and Core Engineering Strategies.
Article in Organic letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this work, we report the synthesis and comprehensive characterization of a new series of fully fused three-dimensional rylenimide-based derivatives featuring extended π-conjugation through core-fusion strategies and tailored side-chain engineering at the imide nitrogen, resulting in molecular architectures with up to 19 fused rings. The effects of π-extension and alkyl/aryl imide substituents on the optical and electrochemical behavior were systematically studied using UV-vis spectroscopy, cyclic voltammetry, and density functional theory calculations. The results demonstrate that combining π-extension with bulky solubilizing groups effectively suppresses undesired π-π interactions, enhances electronic delocalization, and improves device-relevant properties. This molecular design strategy offers a promising platform for the development of next-generation functional
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.